Cybin D/B/A Helus Pharma (HELP) Stock Price & Analysis
Cybin D/B/A Helus Pharma (HELP) closed at USD 10.71 on Thursday, October 29, 2026, down 1.83% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 10.91; the Oct 29, 2026 session ranged USD 10.51–11.3 on volume of 784,988 shares. Market capitalization is $782.47M, with a 52-week range of USD 3.76–15.15 (NGM). Source: Nexqual, retrieved October 29, 2026 at 20:56 UTC.
Also available as compact Markdown for AI agents: nexqual.com/HELP.md
Key facts (HELP)
- Insider open-market purchases, last ~7 months: 9 Form 4 filings, $9.7M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.91 on a 1–5 scale) (11 analysts), mean target USD 41.44 (range 15.16–70.39).
- Total return with dividends: 1Y +49.2% vs S&P 500 +14.4%; 5Y -84.9% vs S&P 500 +79.1%.
- Next earnings: 2026-11-12, EPS estimate USD -1.01, revenue estimate $0K.
Insider purchases (SEC Form 4, open-market, last ~7 months) (HELP)
9 purchases, $9.7M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-09-29 | Cavers Greg | Chief Financial Officer | 3,000 | $39K | 12.91 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-21 | Halstead Michael | Chief Executive Officer | 100,000 | $1.3M | 13.47 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-08 | Glavine Paul | Chief Growth Officer | 100,000 | $1.2M | 12.47 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-08 | Glavine Paul | Chief Growth Officer | 100,000 | $1.2M | 12.47 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-08 | So Eric H. L. | Executive Chair | 100,000 | $1.2M | 12.39 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-04 | So Eric H. L. | Executive Chair | 100,000 | $1.2M | 12.09 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-03 | Glavine Paul | Chief Growth Officer | 100,000 | $1.2M | 11.78 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-01 | So Eric H. L. | Executive Chair | 95,000 | $1.1M | 11.8 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-31 | Glavine Paul | Chief Growth Officer | 90,000 | $1.0M | 11.59 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (HELP)
Consensus Buy (mean 1.91 on a 1–5 scale), 11 analysts; mean target USD 41.44 (low 15.16, high 70.39).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Wells Fargo | Target raised | Overweight | $16 → $22 |
| 2026-09-18 | Barclays | Initiated | Overweight | $35 |
| 2026-08-20 | TD Cowen | Target raised | Buy | $8 → $62 |
| 2026-07-27 | Wells Fargo | Initiated | Overweight | $16 |
| 2026-07-09 | HC Wainwright & Co. | Target lowered | Buy | $95 → $70 |
Total return (dividends reinvested) (HELP)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +49.2% | -84.9% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | +49.4% | -31.4% |
| Volatility (annualized) | 87.8% | 80.9% |
| Max drawdown | -55.6% (Dec 2025→Jun 2026) | -95.3% (Nov 2021→Jun 2026) |
HELP major shareholder filing: Schedule 13D, Sep 9, 2026
So Eric H. L., So Tina filed a Schedule 13D with the SEC on Sep 9, 2026, reporting up to 5.80% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
Investment and company employee incentive awards
Source: SEC EDGAR, Schedule 13D filed Sep 9, 2026. Quoted word for word; Nexqual adds no interpretation.
HELP earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$1.26 | −$1.38 | Beat +8.7% | — |
| — | Quarter ended Mar 31, 2026 | −$1.21 | −$1.14 | Miss −6.1% | — |
| — | Quarter ended Dec 31, 2025 | −$1.36 | −$0.98 | Miss −38.8% | — |
| — | Quarter ended Sep 30, 2025 | −$1.65 | −$1.33 | Miss −24.1% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
HELP recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 27, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 27, 2026 |
| Oct 21, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 21, 2026 |
| Oct 15, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 15, 2026 |
| Oct 8, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 8, 2026 |
| Oct 5, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 1, 2026 |
| Oct 2, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 1, 2026 |
| Oct 1, 2026 | 6-K | Current report (foreign issuer) · period ended Oct 1, 2026 |
| Sep 23, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 22, 2026 |
| Sep 22, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 21, 2026 |
| Sep 21, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 21, 2026 |
| Sep 10, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 10, 2026 |
| Sep 9, 2026 | Schedule 13D | So Eric H. L., So Tina: 5.8% of shares, 5%+ holder that may seek to influence the company “Investment and company employee incentive…” |
| Sep 9, 2026 | 6-K | Current report (foreign issuer) · period ended Sep 9, 2026 |
| Sep 9, 2026 | Schedule 13D | Glavine Paul, PLG Family Trust: 5.8% of shares, 5%+ holder that may seek to influence the company “Investment purposes and Issuer employee incentive…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
HELP analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-1.01 | $-1.07 | +$0.06 | $0 | 6 |
| Next quarter (ends Dec 2026) | $-0.95 | $-1.01 | +$0.06 | $0 | 6 |
| Current fiscal year (ends Mar 2027) | $-4.10 | $-4.35 | +$0.25 | $0 | 5 |
| Next fiscal year (ends Mar 2028) | $-2.47 | $-3.29 | +$0.82 | $11.8M | 2 |
HELP options: expected move
Options price a move of about ±40.8% (±$4.40) by Nov 20, 2026, which includes earnings on Nov 12, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 208.7% | ±40.8% |
| Dec 18, 2026 | 50 | 217.0% | ±61.2% |
| Jan 15, 2027 | 78 | 210.8% | ±73.3% |
| Feb 19, 2027 | 113 | 181.9% | ±77.0% |
| Mar 19, 2027 | 141 | 151.6% | ±72.4% |
| May 21, 2027 | 204 | 149.6% | ±81.4% |
30-day implied volatility 207.8% vs 73.1% realized over the last 30 trading days. Put/call ratio (volume) 0.06. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 20:56 UTC)
| Price | USD 10.71 |
|---|---|
| Change | ▼ 1.83% (down) |
| Previous Close | USD 10.91 |
| Open | USD 10.91 |
| Day Range | USD 10.51 – 11.3 |
| 52-Week Range | USD 3.76 – 15.15 |
| Volume | 784,988 shares |
| Market Cap | $782.47M |
| Exchange | NGM |
Technical Analysis (HELP)
Nexqual's technical model rates HELP "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 20:56 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.01 (neutral) |
| vs SMA50 | Below (USD 12) |
| MACD | -0.36 (negative) |
Analyst Ratings (HELP)
Wall Street analysts rate HELP "Buy" based on 11 analysts, with a mean price target of USD 41.44 (range USD 15.16–70.39), per Nexqual as of October 29, 2026 at 20:56 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 41.44 |
| High Target | USD 70.39 |
| Low Target | USD 15.16 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (HELP)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -1.01 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.26 vs est -1.38 ▲ beat |
| 2026-03-31 | USD -1.21 vs est -1.14 ▼ miss |
| 2025-12-31 | USD -1.36 vs est -0.98 ▼ miss |
| 2025-09-30 | USD -1.65 vs est -1.33 ▼ miss |
Source: Nexqual, October 29, 2026 at 20:56 UTC.
Financials & Fundamentals (HELP)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -86.94% |
| Current Ratio | 10.97 |
| Total Cash | $166.36M |
| Total Debt | $0 |
Source: Nexqual, October 29, 2026 at 20:56 UTC.
Financial Health Score (HELP)
Nexqual rates Cybin D/B/A Helus Pharma's overall financial health "Weak" across five dimensions, as of October 29, 2026 at 20:56 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $166M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$141M (TTM) |
| Efficiency | Critical — ROE -87%, ROA -44.4% |
Ownership (HELP)
| Insider Ownership | +12.90% |
|---|---|
| Institutional Ownership | +41.98% |
| Shares Outstanding | 73.06M |
| Float | 58.10M |
Source: Nexqual, October 29, 2026 at 20:56 UTC.
Leadership (HELP)
Cybin D/B/A Helus Pharma is led by Michael I. Halstead, CEO & Director, per Nexqual as of October 29, 2026 at 20:56 UTC.
| CEO & Director | Michael I. Halstead |
|---|---|
| Chief Financial Officer | Greg Cavers |
| Chief Operating Officer | Aaron Bartlone |
| Chief Scientific Officer | Alex L. Nivorozhkin |
Major Backers & Investors (HELP)
Notable institutional backers of Cybin D/B/A Helus Pharma include Venrock Adviser, LLC, Orbimed Advisors LLC., Adage Capital Partners GP L.L.C., according to Nexqual as of October 29, 2026 at 20:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Venrock Adviser, LLC | 4.83% |
| Orbimed Advisors LLC. | 4.1% |
| Adage Capital Partners GP L.L.C. | 3.83% |
| Millennium Management | 3.3% |
| Rosalind Advisors, Inc. | 2.45% |
| Sphera Funds Management Ltd. | 2.03% |
| Acorn Capital Advisors, LLC | 1.93% |
| DCF Advisers, LLC | 1.8% |
Source: Nexqual, October 29, 2026 at 20:56 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 9.56 | ▼ 35.45% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:56 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt